Skip to main content

Table 1 CSFV-specific neutralizing antibody titers in pigs immunized with BV-VSVG-ED-pFc-CMV-S/P-E2 at different days post-immunization

From: Surface displaying of swine IgG1 Fc enhances baculovirus-vectored vaccine efficacy by facilitating viral complement escape and mammalian cell transduction

Groups Pig No. Days post-immunization
0 7 14 21 28
NAbs
A 039 <1 <1 <1 <1 <1
  075 <1 <1 <1 <1 <1
  086 <1 <1 <1 <1 <1
  116 <1 <1 <1 <1 <1
  200 <1 <1 <1 <1 <1
  \(\overline{X}\) ± S <1 <1 <1 <1 <1
B 022 <1 6 16 64 128
  046 <1 8 16 64 128
  105 <1 6 16 64 128
  142 <1 8 24 80 144
  183 <1 8 16 64 108
  \(\overline{X}\) ± S <1 7.2 ± 1.1 17.6 ± 3.6 67.2 ± 7.2 131.5 ± 12.8
C 035 <1 6 8 16 44
  056 <1 8 8 16 64
  073 <1 6 8 32 64
  117 <1 8 12 16 64
  152 <1 4 8 16 64
  \(\overline{X}\) ± S <1 6.4 ± 1.7 8.8 ± 1.8 19.2 ± 7.2 60 ± 8.9
D 026 <1 6 12 48 84
  084 <1 8 16 48 96
  093 <1 6 12 64 96
  128 <1 8 16 48 100
  192 <1 4 16 64 88
  \(\overline{X}\) ± S <1 6.4 ± 1.7 14.4 ± 2.2 54.4 ± 8.8 95.2 ± 6.6
  1. Four groups (n = 5) of 4 week old pigs were immunized with BV-VSVG-ED-pFc-CMV-S/P-E2. Serum were collected at different time after the immunization, and subjected to detection of CSFV-specific neutralizing antibodies (NAbs) by serum-virus neutralization test (SNT). \(\overline{X}\) ± S: mean ± standard deviation. Group A-D indicate pigs immunized with PBS, CSFV commercial vaccine C-strain, BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-CMV-S/P-E2, respectively.